Latest Research in Acute Myeloid Leukemia Research
18 research papers · 2026 median publication year
Top Research Topics in Acute Myeloid Leukemia Research
- Acute Myeloid Leukemia Research — 16 papers
- Neutropenia and Cancer Infections — 1 papers
- Acute Lymphoblastic Leukemia research — 1 papers
Highest-Cited Papers
- Prolonged treatment-free remission after venetoclax in combination with a hypomethylating agent in acute myeloid leukemia with inv(16)
- Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation
- Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes
- DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
- Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival
- Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis
- Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine
- Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia
- OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML
- Successful treatment of B-cell acute lymphoblastic leukemia with SET-NUP214 rearrangement using venetoclax: A first case report and literature review
- Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia
- Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting
- A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia
- Real-world clinical outcomes of newly diagnosed AML unfit for intensive chemotherapy treated with venetoclax and azacitidine: does it depend on the number of days of venetoclax administration?
- Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms
- Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry
- Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience
- Weekly Metronomic Venetoclax and Decitabine/Cedazuridine in Acute Myeloid Leukemia Patient Declining Blood Transfusion